▎WuXiEdited by the Kant Content Team

‍AstraZeneca and MSD announced the long-term results of the Phase 3 clinical trial OlympiA today. The study showed,PARP inhibitor Lynparza (olaparib) in germlineBRCAContinued significant improvement in overall survival (OS), invasive disease-free survival (IDFS), and distant disease-free survival (DDFS) in HER2-negative high-risk early breast cancer patients with mutations (gBRCAm).

At a median follow-up time of 6.1 years, in patients who had completed local treatment and standard neoadjuvant or adjuvant chemotherapy,Lynparza reduced the risk of death by 28% compared to placebo (HR=0.72; 95% CI: 0.56-0.93). In addition, 87.5% of patients treated with Lynparza remained alive, compared to 83.2% in the placebo group.

▲Summary of Efficacy Results from the OlympiA Trial (Image Source: Reference [1])

Lynparza also demonstrated sustained and clinically meaningful improvements in the clinical endpoints of IDFS and DDFS. Compared with placebo, Lynparza reduced the risk of invasive breast cancer recurrence, second cancers, or death by 35% (HR=0.65; 95% CI: 0.53-0.78) and decreased the risk of distant disease recurrence or death by 35% (HR=0.65; 95% CI: 0.53-0.81).

Lynparza is a "first-in-class" PARP inhibitor and also the first synthetic lethal targeted therapy drug, used to target cells/tumors with homologous recombination repair (HRR) defects (such as those carryingBRCA1And/OrBRCA2Mutated cells).Based on the results of the Phase 3 clinical trial OlympiA, Lynparza has been approved in the United States, the European Union, Japan, and many other countries and regions for the treatment of gBRCAm, HER2-negative high-risk early breast cancer. Additionally, it has also been approved in the United States, the European Union, Japan, and many other countries and regions for the treatment of gBRCAm, HER2-negative metastatic breast cancer.

Disclaimer: The content team of WuXi AppTec focuses on introducing the research progress in global biopharmaceuticals and health. This article is for information exchange purposes only, and the views expressed in the article do not represent the position of WuXi AppTec, nor does it indicate that WuXi AppTec supports or opposes these views. This article is not a recommendation for treatment plans. If you need guidance on treatment options, please visit a正规 hospital.

Copyright Statement: This article is from the WuXi AppTec content team. Individuals are welcome to share it on their social media circles, but unauthorized reproduction by media or institutions in any form to other platforms is prohibited. For authorization to reproduce, please reply with "reprint" on the "WuXi AppTec" WeChat Official Account to obtain reprint guidelines.